Location History:
- Mission Viejo, CA (US) (1976 - 1977)
- El Paso, TX (US) (1977)
Company Filing History:
Years Active: 1976-1977
Title: **Dennis A. Shuman: Innovator in Purine Derivatives**
Introduction
Dennis A. Shuman, based in Mission Viejo, California, is a notable inventor with a focus on purine derivatives. Holding three patents to his name, his contributions have significant implications in the field of biochemistry and pharmacology.
Latest Patents
Among his innovative works, Dennis's latest patents include the formulation of 6,8-disubstituted purine derivatives of 9-β-D-ribofuranosyl. This complex compound structure exhibits a variety of substituents like hydrogen, halogens, and acyl groups. The compounds are known for their biological activities such as phosphodiesterase inhibition and protein kinase activation, which can lead to therapeutic effects including increased cardiac output and lowered blood pressure. Additionally, he has developed 6-Aminocarbonyl purine 3',5'-cyclic nucleotides, which have shown superior activation properties compared to adenosine 3',5'-cyclic phosphate (cAMP), giving rise to advancements in medicinal applications.
Career Highlights
Dennis is currently associated with Icn Pharmaceuticals, Inc., where his research endeavors focus on pharmaceutical innovations. His patents reflect a strong commitment to developing compounds that demonstrate significant biological activity, influencing treatments and therapies in medicine.
Collaborations
Throughout his career, Dennis has collaborated with skilled professionals, including Roland K. Robins and Kay H. Boswell. These partnerships have contributed to the enhanced development of his patented innovations and research endeavors, resulting in substantial contributions to the scientific community.
Conclusion
In conclusion, Dennis A. Shuman stands as a pioneering figure in the field of purine derivatives. With a focus on creating compounds with promising biological effects, his inventions hold the potential to impact therapeutic practices significantly. As he continues his work at Icn Pharmaceuticals, his contributions will likely foster further innovations and advancements within the pharmaceutical industry.